12885_2018_4692_MOESM2_ESM.docx (18.95 kB)
Additional file 2: of Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
journal contribution
posted on 2018-08-06, 05:00 authored by Kyriakos Papadopoulos, Eytan Ben-Ami, Amita Patnaik, Denise Trone, Jianke Li, George DemetriMost common (reported in âĽ2 patients) treatment-emergent adverse events (safety population). (DOCX 18 kb)